Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder

Deerfield Management formed Boulevard Bio with scientific co-founders Georg Schett and Frank Nestle. The startup’s lead program is in early clinical development for an autoimmune kidney disorder, and could offer dosing advantages over a recently approved Vera Therapeutics medicine and a Vertex Pharmaceuticals drug currently under FDA review. The post Startup Boulevard Bio Launches With…

Read More

Ambulatory Growth Demands a New Operating Model

While organizations have invested heavily in expanding ambulatory networks, many are discovering that operational workflows have not evolved at the same pace. The result is a growing gap between demand and the systems designed to manage it. The post Ambulatory Growth Demands a New Operating Model appeared first on MedCity News.

Read More